Trial · NCT00673387
Results by group636
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 636
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Placebo | -2.01 | 95% Confidence Interval -3.76 to -0.26 | Percentage change in kg | |
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg | -5.47 | 95% Confidence Interval -7.19 to -3.76 | Percentage change in kg | |
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Metreleptin 5.0 mg | -5.83 | 95% Confidence Interval -7.72 to -3.95 | Percentage change in kg | |
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Pramlintide 180 mcg + Metreleptin 2.5 mg | -6.85 | 95% Confidence Interval -8.61 to -5.08 | Percentage change in kg | |
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Pramlintide 180 mcg + Metreleptin 5.0 mg | -6.61 | 95% Confidence Interval -8.41 to -4.82 | Percentage change in kg | |
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg + Metreleptin 1.25 mg | -6.39 | 95% Confidence Interval -8.18 to -4.59 | Percentage change in kg | |
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg + Metreleptin 2.5 mg | -6.98 | 95% Confidence Interval -8.79 to -5.17 | Percentage change in kg | |
| Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg + Metreleptin 5.0 mg | -7.02 | 95% Confidence Interval -8.94 to -5.10 | Percentage change in kg | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Placebo | Weight Loss >=5% | 10 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg | Weight Loss >=5% | 27 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Metreleptin 5.0 mg | Weight Loss >=5% | 18 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 180 mcg + Metreleptin 2.5 mg | Weight Loss >=5% | 27 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 180 mcg + Metreleptin 5.0 mg | Weight Loss >=5% | 27 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg + Metreleptin 1.25 mg | Weight Loss >=5% | 23 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg + Metreleptin 2.5 mg | Weight Loss >=5% | 29 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg + Metreleptin 5.0 mg | Weight Loss >=5% | 25 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Placebo | Weight Loss >=5% and <10% | 7 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 360 mcg | Weight Loss >=5% and <10% | 14 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Metreleptin 5.0 mg | Weight Loss >=5% and <10% | 6 | participants | |
| Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population | Pramlintide 180 mcg + Metreleptin 2.5 mg | Weight Loss >=5% and <10% | 14 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00673387/results